NCT00676520View on ClinicalTrials.gov

XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1)

CompletedOBSERVATIONAL
Enrollment

8,053

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Coronary Artery Disease
Interventions
DEVICE

XIENCE V® Everolimus Eluting Coronary Stent

Single-arm study designed to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.

Trial Locations (1)

95054

Abbott Vascular, Santa Clara

Sponsors
All Listed Sponsors
lead

Abbott Medical Devices

INDUSTRY

NCT00676520 - XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1) | Biotech Hunter | Biotech Hunter